Anti-CD20 for IHC / MS4A1, clone MSVA-020R

Antibody in 1X PBS with 0.05% BSA, 0.05% sodium azide. CD20 (MS4A1) is a B cell-specific transmembrane protein that functions in calcium signaling and regulation of B lymphocyte activation and differentiation. It is widely used as a definitive marker of mature B cells and is a cornerstone target in diagnostic immunohistochemistry. CD20 Antibody for IHC is designed for detection of MS4A1 expression in formalin-fixed, paraffin-embedded (FFPE) tissues, enabling precise visualization of B cell populations and lymphoid architecture in tissue sections.In immunohistochemistry, CD20 antibody, also known as MS4A1 antibody or B cell marker antibody, produces strong and sharply defined membranous staining that clearly delineates B lymphocytes. In FFPE human tissue microarrays (TMAs), this antibody demonstrates highly consistent staining across a wide range of normal tissues, with intense membranous labeling in lymph node follicles, tonsil germinal centers, spleen white pulp, and other lymphoid compartments. The use of large-scale TMAs highlights reproducibility across hundreds of tissue cores, confirming both specificity and low background in non-lymphoid epithelial and stromal tissues.CD20 Antibody for IHC is particularly valuable in cancer tissue microarray analysis, where it robustly identifies B cell-derived malignancies. In TMA panels containing diverse tumor types, strong and diffuse membranous staining is observed in B cell lymphomas, including diffuse large B cell lymphoma and other non-Hodgkin lymphomas. This staining provides clear contrast against most non-hematologic malignancies, which typically show little to no CD20 expression. Additionally, the antibody enables visualization of tumor-infiltrating B lymphocytes within the tumor microenvironment, supporting studies of immune contexture and lymphoid involvement in cancer.The membranous staining pattern produced by CD20 immunohistochemistry is highly specific and aligns with the known surface localization of the protein. Across FFPE TMAs, the antibody consistently delivers clean signal with minimal non-specific staining, allowing accurate interpretation of staining intensity and distribution across both normal and malignant tissues. The standardized format of tissue microarrays further strengthens confidence in cross-sample comparisons and biomarker validation studies.Functionally, CD20 is expressed during most stages of B cell development but is absent in early progenitors and terminally differentiated plasma cells, making it a highly selective lineage marker. This restricted expression pattern enhances its diagnostic utility in immunohistochemistry, particularly for distinguishing B cell lymphomas from other hematologic and non-hematologic malignancies. Overall, CD20 Antibody for IHC provides reliable, high-contrast membranous staining in FFPE tissue microarrays, making it an essential tool for lymphoid tissue evaluation, lymphoma classification, and tumor microenvironment analysis.This CD20 antibody is also part of a broader collection of IHC antibodies validated by tissue microarray analysis, supporting consistent staining across normal and cancer tissues.